Recursion (RXRX) CEO reports tax RSU withholding and 40K share sale
Rhea-AI Filing Summary
Recursion Pharmaceuticals (RXRX) CEO/Director Form 4 shows routine equity activity. On 11/17/2025, 40,390 Class A shares were withheld at $4.14 to cover tax obligations from net-settled restricted stock units, leaving 913,839 Class A shares directly owned. On 11/19/2025, the insider converted 40,000 Class B shares into Class A at $0 and sold 40,000 Class A shares at $4.16 under a Rule 10b5-1 trading plan adopted on May 12, 2025, maintaining direct ownership at 913,839 Class A shares.
The insider also reports derivative holdings, including Class B shares convertible into Class A with no expiration date and multiple stock options with exercise prices ranging from $2.48 to $11.40 and expirations extending to 2035. Some Class B holdings are reported indirectly through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Class B Common Stock | 40,000 | $0.00 | -- |
| Conversion | Class A Common Stock | 40,000 | $0.00 | -- |
| Sale | Class A Common Stock | 40,000 | $4.16 | $166K |
| Tax Withholding | Class A Common Stock | 40,390 | $4.14 | $167K |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Footnotes (1)
- Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee. The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
FAQ
What insider transactions did the RXRX CEO report on this Form 4?
The CEO of Recursion Pharmaceuticals (RXRX) reported three main transactions: 40,390 Class A shares withheld on 11/17/2025 to cover taxes on restricted stock units, the conversion of 40,000 Class B shares into Class A on 11/19/2025 at $0, and the sale of 40,000 Class A shares on 11/19/2025 at $4.16.
Was the RXRX CEO stock sale made under a Rule 10b5-1 trading plan?
Yes. The conversion and sale of 40,000 Class A shares on 11/19/2025 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025.
What is the relationship between RXRX Class B and Class A Common Stock for this insider?
Each reported share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
What indirect RXRX holdings does the CEO report?
The CEO reports indirect holdings of Class B Common Stock convertible into Class A through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust, where the CEO is a member, manager, or trustee.
What stock options in RXRX does the CEO hold according to this Form 4?
The CEO reports several stock options (rights to buy Class A Common Stock) with exercise prices including $10.09, $7.25, $8.55, $11.40, and $2.48, with expirations between 02/04/2032 and 02/03/2035, and vesting monthly under the schedules described.